Deutsche Bank AG set a $17.00 target price on Intersect ENT Inc. (NASDAQ:XENT) in a research report report published on Tuesday. The firm currently has a a hold rating on the stock.

XENT has been the subject of several other reports. Canaccord Genuity restated a buy rating and set a $20.00 price target on shares of Intersect ENT in a research note on Thursday, August 4th. BTIG Research assumed coverage on Intersect ENT in a research note on Tuesday, July 12th. They issued a neutral rating for the company. Wedbush reiterated an outperform rating and issued a $25.00 target price on shares of Intersect ENT in a research note on Wednesday, August 3rd. Piper Jaffray Cos. reiterated an overweight rating and issued a $21.00 target price on shares of Intersect ENT in a research note on Friday, August 26th. Finally, Zacks Investment Research upgraded Intersect ENT from a hold rating to a buy rating and set a $17.00 target price for the company in a research note on Saturday, August 6th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Intersect ENT has a consensus rating of Buy and an average target price of $22.00.

Intersect ENT (NASDAQ:XENT) traded down 3.19% during midday trading on Tuesday, reaching $16.70. The company had a trading volume of 71,593 shares. Intersect ENT has a 12 month low of $11.88 and a 12 month high of $23.00. The firm’s market capitalization is $475.18 million. The firm’s 50-day moving average price is $15.80 and its 200 day moving average price is $15.43.

Intersect ENT (NASDAQ:XENT) last released its earnings results on Tuesday, August 2nd. The company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.05. Intersect ENT had a negative return on equity of 23.31% and a negative net margin of 42.97%. The firm had revenue of $19.30 million for the quarter, compared to the consensus estimate of $18.91 million. During the same period in the prior year, the business posted ($0.23) earnings per share. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. Equities analysts anticipate that Intersect ENT will post ($0.96) earnings per share for the current fiscal year.

In other Intersect ENT news, VP Amy Wolbeck sold 28,664 shares of the stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $15.83, for a total transaction of $453,751.12. Following the transaction, the vice president now owns 18,076 shares of the company’s stock, valued at approximately $286,143.08. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP James Stambaugh sold 3,977 shares of the stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $17.00, for a total value of $67,609.00. Following the transaction, the vice president now directly owns 27,977 shares in the company, valued at approximately $475,609. The disclosure for this sale can be found here. Company insiders own 13.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XENT. Allianz Asset Management AG increased its position in Intersect ENT by 0.7% in the second quarter. Allianz Asset Management AG now owns 155,938 shares of the company’s stock worth $2,016,000 after buying an additional 1,098 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Intersect ENT by 19.0% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,947 shares of the company’s stock worth $232,000 after buying an additional 2,869 shares in the last quarter. Swiss National Bank increased its position in Intersect ENT by 17.7% in the second quarter. Swiss National Bank now owns 34,600 shares of the company’s stock worth $447,000 after buying an additional 5,200 shares in the last quarter. American International Group Inc. increased its position in Intersect ENT by 75.5% in the second quarter. American International Group Inc. now owns 14,684 shares of the company’s stock worth $190,000 after buying an additional 6,318 shares in the last quarter. Finally, Raymond James & Associates increased its position in Intersect ENT by 8.6% in the second quarter. Raymond James & Associates now owns 88,125 shares of the company’s stock worth $1,139,000 after buying an additional 7,013 shares in the last quarter. 77.81% of the stock is currently owned by institutional investors.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

5 Day Chart for NASDAQ:XENT

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.